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Abstract
Arrhythmogenic right ventricular dysplasia (ARVD) is a genetic cardiomyopathy characterized
clinically by ventricular arrhythmias and progressive right ventricular (RV) dysfunction. The
histopathologic hallmark is fibro-fatty replacement of RV myocardium. It is inherited in an
autosomal pattern with variable penetrance. ARVD is unique in that it most commonly presents in
young, otherwise healthy and highly athletic individuals. The cause of ARVD is not well-known but
recent evidence suggests strongly that it is a disease of desmosomal dysfunction. The disease
involvement is not limited only to the RV as left ventricle (LV) has also been reportedly affected.
Diagnosis of ARVD is challenging and is currently based upon a multi-disciplinary work-up of the
patient as defined by the Task Force. Currently, implanted cardioverter defibrillators (ICD) are
routinely used to prevent sudden death in patients with ARVD. Cardiovascular MR is an important
non-invasive diagnostic modality that allows both qualitative and quantitative evaluation of RV. This
article reviews the genetics of ARVD, current status and role of CMR in the diagnosis of ARVD
and LV involvement in ARVD.
Background
Arrhythmogenic right ventricular dysplasia (ARVD) is a
progressive cardiomyopathy primarily affecting the right
ventricle (RV) and is characterized by fatty/fibro-fatty
replacement with myocyte loss, ventricular arrhythmias of
left bundle branch block pattern (LBBB) and right heart
failure. Increasing evidence suggests that ARVD is a dis-
ease of desmosomal dysfunction. ARVD can exist in both
sporadic and familial forms with the familial form show-
ing a predominantly autosomal dominant inheritance
pattern with variable penetrance. The exact prevalence is
unknown, but it is estimated to be 1:5000 in the United
States. The clinical onset of ARVD is often delayed to ado-
lescence or early adulthood. It is more commonly seen in
males and people engaged in athletics and competitive
sports.
ARVD accounts for up to 5% of sudden deaths in young
individuals less than 35 years of age in the United States,
and 25% of exercise-related deaths in Veneto, Italy [1,2].
The death rate for patients with ARVD has been estimated
at 2.5% per year [3]. The main differential diagnosis of
ARVD consists of right ventricular outflow tract (RVOT)
tachycardia, sarcoidosis, idiopathic dilated cardiomyopa-
thy, isolated myocarditis, adipomatosis cordis, mitral
valve prolapse, non-coronary precordial ST-segment ele-
vation (Brugada syndrome) and the Uhl anomaly, which
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is characterized by a paper-thin RV due to almost com-
plete absence of myocardial fibers [4].
The diagnosis of ARVD is based upon a set of major and
minor criteria proposed by the Task Force of cardiomy-
opathies in 1994 [5]. The diagnostic criteria (Table 1) are
based upon a number of diverse genetic, electrocardio-
graphic, pathophysiologic, histopathologic and imaging
abnormalities. Patients must have either two major crite-
ria, one major and two minor criteria, or four minor crite-
ria to be labeled as affected with ARVD.
Important morphological patterns of ARVD manifesta-
tion include myocyte loss with fibro-fatty replacement of
the ventricular myocardium, focal thinning of ventricular
free wall, wall hypertrophy, focal bulging of the RV wall in
diastole and RVOT enlargement. Functionally, the disease
may result in global or regional contraction abnormali-
ties, RV systolic/diastolic dysfunction, RV dilatation and
RV aneurysms. The imaging modalities used for RV assess-
ment in ARVD include conventional angiography,
echocardiography, radionuclide angiography, computed
tomography (CT) and cardiovascular magnetic resonance
(CMR). The standard of reference for the diagnosis of
ARVD has been the histo-pathological demonstration of
fibro-fatty replacement of the RV myocardium at either
surgery or autopsy. Unfortunately biopsy carries risk of
perforation and has low sensitivity on account of the seg-
mental nature of fatty infiltration. The major therapeutic
decision involved in the care of a patient with ARVD
involves the decision to implant an implantable cardio-
verter defibrillator (ICD). Anti-arrhythmic drug therapy
and catheter ablation may be useful to decrease the fre-
quency of sustained ventricular arrhythmias and ICD fir-
ing. In case of intractable RV failure or incessant
ventricular arrhythmias which are refractory to anti-
Table 1: Criteria for diagnosis of ARVD [5]
I. Global and/or Regional Dysfunction and Structural Alterations*
• Major
Severe dilatation and reduction of right ventricular ejection fraction with no (or only mild) left ventricular impairment
Localized right ventricular aneurysms (akinetic or dyskinetic areas with diastolic bulging)
Severe segmental dilatation of the right ventricle
￿ Minor
Mild global right ventricular dilatation and/or ejection fraction reduction with normal left ventricle
Mild segmental dilatation of the right ventricle
Regional right ventricular hypokinesia
II. Tissue Characterization of Wall
￿ Major
Fibrofatty replacement of myocardium on endomyocardial biopsy
III. Repolarisation Abnormalities
￿ Minor
Inverted T waves in right precordial leads (V2 and V3) in people aged >12 years, in absence of right bundle branch block
IV. Depolarization/Conduction Abnormalities
￿ Major
Epsilon waves or localized prolongation (>110 ms) of the QRS complex in right precordial leads (V1 - V3)
￿ Minor
Late potentials (signal-averaged ECG)
V. Arrhythmias
￿ Minor
Left bundle branch block type ventricular tachycardia (sustained and non-sustained) by ECG, Holter or exercise testing
Frequent ventricular extra-systoles (>1000/24 hours) by Holter
VI. Family History
￿ Major
Familial disease confirmed at necropsy or surgery
￿ Minor
Family history of premature sudden death (<35 years) due to suspected right ventricular dysplasia
Familial history (clinical diagnosis based on present criteria)
*Detected by echocardiography, angiography, magnetic resonance imaging, or radionuclide scintigraphy.
The diagnosis of ARVD would be fulfilled by the presence of two major, or one major plus two minor criteria or four minor criteria from different 
groups.Journal of Cardiovascular Magnetic Resonance 2008, 10:32 http://www.jcmr-online.com/content/10/1/32
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arrhythmic drug therapy and/or catheter ablation, cardiac
transplantation may be an option for treating patients
with ARVD.
As novel mutations in desmosomal proteins are being
reported, the relationships between genetic mutation and
phenotypic expression are beginning to be understood,
particularly in the context of CMR diagnosis. This review
discusses these relationships and the role of CMR for eval-
uation of patients with ARVD.
Genetic basis of ARVD
ARVD is known to occur in both sporadic and familial
forms, with familial disease accounting for an estimated
30% to 80% cases [6]. Familial ARVD is primarily auto-
somal dominant, with several sub-types identified and
mapped to distinct genetic loci to date – ARVD1
(14q24.3) [7], ARVD2 (1q42) [8], ARVD3 (14q11-q12)
[9], ARVD4 (2q32) [10], ARVD5 (3p23) [11], ARVD6
(10p12-p14) [12], ARVD7 (10q22) [13], ARVD8 (6p24)
[14], ARVD9 (12p11) [6], ARVD10 (8q12) and ARVD11
(18q21) [15]. Besides, two autosomal recessive syndro-
mic forms of ARVD – Naxos disease (17q21) and Carvajal
syndrome (6p23-24) are also known which involve skin
and hair as well as heart [16-18]. An autosomal dominant
association of non-epidermolytic palmo-plantar kerato-
derma, woolly hair, and dilated right ventricle was
reported by Tosti et al. in an Italian family [19].
To date, seven genes have been implicated in the domi-
nant and recessive ARVD, including transforming growth
factor-  β3 (TGFβ3) in ARVD1 [20], cardiac ryanodine
receptor (RYR2) in ARVD2 [21] and five desmosomal pro-
teins: desmoplakin (DSP) in ARVD8 [14] as well as Carva-
jal syndrome [16], plakophilin-2 (PKP-2) in ARVD9 [6],
desmoglein-2 (DSG2) in ARVD10 [15], desmocollin-2
(DSC2) in ARVD11 [15] and desmocollin-2 (DSC2) [22]
and junctional plakoglobin (JUP) in Naxos disease [17]
and also in an autosomal dominant form of ARVD in a
German family [23] (Table 2). It is notable that the major-
ity of these genes are involved with cell to cell connection
in the region of the cardiac desmosome.
ARVD shows polymorphic expressivity with variable clin-
ical expression of PKP2 mutations even among first-
degree relatives ranging from a complete lack of symp-
toms to a severe disease phenotype experiencing sudden
cardiac death (SCD)/right or biventricular heart failure.
This large heterogeneity in clinical expression can be
attributed to factors such as involvement of different
desmosomal genes, different mutations within the same
gene and effect-modification by other genetic and envi-
ronmental factors. Dominant ARVD due to PKP2 muta-
tions has also widely been shown to have an age-
dependent, variable penetrance which could again be
attributed to modifier genes, environmental influences
and gender effects [24-29]. In contrast to dominant dis-
ease and heterozygous recessive carriers, homozygous
recessive forms of ARVD show 100% penetrance by ado-
lescence, with syncope as the usual symptomatic presen-
tation [30].
The genetic patterns of ARVD are complex, with heteroge-
neity in causative genetic mutations and abnormality
within the same gene showing varied patterns of inherit-
ance and phenotypic expression and vice versa. Mutations
in DSP have been shown to underlie autosomal dominant
and recessive skin disorders, with or without cardiac
involvement [31]. Awad et al reported the first case of
recessive ARVD caused by a novel cryptic splice mutation
in PKP2 [32] and Francis et al reported recessive ARVD
with anterior polar cataracts in a consanguineous family
from Argentina [33]. Djabali et al reported extensive locus
heterogeneity for Naxos syndrome and described exclu-
sion of DSP, JUP, and several other components of the
desmosome in two families with Naxos syndrome
[34,35]. It is speculated that like other inherited cardio-
vascular diseases particularly hypertrophic cardiomyopa-
thy and long QT syndrome, a small minority of ARVD
cases may have more than one co-existent mutations.
Although this is yet to be proven, digenic inheritance with
a gene dose effect might however account for many unex-
plained observations, including relatives with mild but
Table 2: Candidate genes for ARVD [37]
Components of the desmosome





Tyrosine kinases that phosphorylate desmosomal proteins









Components of dystrophic-glycoprotein complex
Desmin
Laminin receptor-1
Myotonic dystrophy protein kinase-1
Transforming growth factor β3*
*genes that have been definitively implicated in ARVD.
Of the other genes listed above, many are currently under 
investigation for a potential etiological role in ARVDJournal of Cardiovascular Magnetic Resonance 2008, 10:32 http://www.jcmr-online.com/content/10/1/32
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definite disease affliction who are "negative" for the fam-
ily mutation and variable penetrance and expressivity in
families with apparently identical genotype [36].
Gene expression in the pathogenesis of ARVD
Identification of causative desmosomal mutations has
resulted in ARVD to be increasingly viewed upon as a
desmosomal disease and has provided insight into its
pathogenesis. Mutations affecting components of the car-
diac desmosome are believed to disrupt cell-cell adhesion,
provoking detachment of myocytes particularly under
conditions of mechanical stress. This, in turn, might lead
to apoptosis and cell necrosis, predisposing to inflamma-
tion and repair by fibro fatty substitution.
Accordingly, early ARVD shows predilection for the
regions of heart with relatively thinner walls and high
shear stress – the subtricuspid portion, outflow tract, apex
and mid-free wall of the RV ("triangle of dysplasia") and
the inferior wall septal junction and infero-lateral wall of
the LV. Young individuals and athletes are predisposed
because of high level of physical activity and resultant
greater strain on heart. Gap junction remodeling associ-
ated with impaired mechanical coupling at cell adhesion
junctions may result in a predisposition to the arrhyth-
mogenicity seen in ARVD. Furthermore, adrenergic stimu-
lation during highly strenuous activity may precipitate
arrhythmic events in patients with ARVD. Desmosomal
mutations may induce nuclear protein dysfunction as
desmosomal proteins are believed to be involved in regu-
lation of transcription. Desmosomal mutations may also
heighten the pathogenic role of viral infection speculated
in the causation of ARVD [34,36,37].
A pathogenic role of cytoplasmic calcium overload is
shown by the association of mutations in RYR2 with
ARVD2. This type of ARVD has a very different clinical
presentation and is rather distinct from the more com-
mon types of ARVD. RYR2 has also been independently
implicated in isolated familial catecholaminergic poly-
morphic VT (CPVT) reflecting possibly different muta-
tions within the same gene and the probable role of effect-
modification by individual genetic make-ups and envi-
ronmental influences in different phenotypic expressions
of the same genetic abnormality [38]. Finally, alterations
in cytokines such as TGFβ3 may also contribute to disease
progression as TGFβ3 is known to induce fibrotic
response by stimulating mesenchymal cells and has been
shown to modulate expression of genes encoding desmo-
somal proteins in different cell types and regulate stability
of cell-cell junctional complexes [20]. A link between the
mutations in the genes involved in ARVD and induction
of apoptotic death of myocardiocytes is believed to exist
but remains speculative and is yet to be proven [39].
Role of genetic screening and Task Force diagnostic 
criteria
There have been a number of studies addressing the issue
of prevalence of PKP2 mutations in different groups of
ARVD patients [6,25,26,28,40]. Both Dalal et al in the
United States [25] and van Tintelen et al in the Nether-
lands [26] working independently found the prevalence
of mutations in PKP2 among unrelated ARVD probands
to be 43%. Tintelen et al additionally discovered that the
rate of PKP2 mutations was as high as 70% in cases with
familial ARVD and no PKP2 mutations were identifiable
in cases with non-familial sporadic phenotype. The high
prevalence of PKP2 mutations among ARVD patients
points towards a potential role of mutation analysis in
PKP2 mutation positive ARVD cases and their family
members [25]. Cases with PKP2 mutations did not differ
significantly from those without PKP2 mutations with
regard to clinical characteristics and outcomes, except for
earlier age of first clinical presentation and first arrhyth-
mia and more frequent negative T waves in V2 and V3 [29].
Additionally, patients with a PKP2 mutation undergo ICD
interventions irrespective of the classic risk factors deter-
mining ICD intervention in ARVD patients [25]. Although
molecular genetic analysis is unlikely to contribute signif-
icantly to prediction of clinical phenotype and risk strati-
fication, it has potential for family screening and
preclinical diagnosis, particularly for patients with early/
incomplete disease expression [25,29].
In keeping with variable penetrance and multi-factorial
causation of ARVD, the mere inheritance of a mutation
previously identified in a proband does not imply a diag-
nosis of ARVD in a family member, in the absence of clin-
ical diagnostic criteria. Conversely, a fully negative family
history could suggest a case of novel mutation or alterna-
tively, a different disease mimicking ARVD such as sar-
coidosis, chagas disease, enterovirus infection, chronic
right-side myocarditis or sub-acute bartonella infection
[39]. The prognostic value of early identification of
asymptomatic gene carriers may be limited because a reli-
able algorithm for primary prevention of sudden death in
familial ARVD is lacking and risk stratification in asymp-
tomatic relatives has not been systematically addressed
[29,41].
In order to account for the broader spectrum of disease in
familial ARVD, it has been suggested that the Task Force
criteria be modified such that the presence of any minor
criterion in first degree relative of a proven case of ARVD
be regarded as clinical disease expression [42,43]. Syrris et
al [28] found that the application of modified criteria
does expand the diagnostic yield but also may lead to false
positives because several family members assumed to be
clinically affected were subsequently found to be gene
negative. Thus to date the interpretation of minor repo-Journal of Cardiovascular Magnetic Resonance 2008, 10:32 http://www.jcmr-online.com/content/10/1/32
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larisation abnormalities in first-degree relatives remains
inconclusive.
In summary, a positive genetic result can only be a part of
a more comprehensive and multi-disciplinary diagnostic
protocol and work-up involving ECG, arrhythmic, mor-
pho-functional, histo-pathological, and clinical/molecu-
lar genetic findings [29]. More complete understanding of
the underlying genetic basis and the pathogenesis of
ARVD will facilitate diagnosis, prognostication and thera-
peutic decision-making in patients which would be of
great significance since adverse clinical outcomes such as
SCD occur without premonitory symptoms in many
cases.
CMR of ARVD
CMR has emerged as an important imaging modality in
the diagnosis and evaluation of patients of ARVD. Among
all other clinical imaging techniques, CMR allows clearest
visualization of the RV in view of its three dimensional (3-
D), multi-planar capabilities with excellent spatio-tempo-
ral resolution and improved contrast between blood pool
and myocardium [44,45]. CMR can also specifically delin-
eate intra-myocardial fatty infiltration which can be
observed as an area of high signal intensity (Figure 1A) on
T1 weighted images. CMR additionally offers unique fea-
tures such as identification of arrhythmogenic foci, veloc-
ity mapping of tricuspid flow, objective quantified
analysis of RV mechanics using CMR tagging [46] and
assessment of ventricular regional, global diastolic and
systolic function [44,45]. Unlike other techniques like
echocardiography, the 3-D data-set acquired by CMR can
be sampled in any plane, making CMR ideal for serial
evaluation of the same patient over time [47]. CMR is
non-invasive and does not require intravenous contrast or
ionizing radiation making it a suitable modality for fol-
low-up in ARVD patients who are frequently young and
require a number of repeated examinations. CMR results
have been shown to correlate well with RV angiography
[48-50], endomyocardial biopsy [51] and echocardiogra-
phy [50] and can well complement them and other inves-
tigations in the diagnosis, work-up and follow-up in this
population of patients. It is because of these reasons that
CMR appears to be an ideal tool for evaluation of cardiac
structure and function in ARVD.
CMR abnormalities in ARVD can broadly be divided into
two groups: 1) functional abnormalities which include
regional wall motion abnormalities (RWMAs), focal
aneurysms (Figure 2), RV dilatation (Figure 3) and RV
diastolic/systolic dysfunction 2) morphological abnor-
malities which include intra-myocardial fatty infiltration
(Figure 1), focal wall thinning, wall hypertrophy, trabecu-
lar hypertrophy and disarray (Figure 4), moderator band
hypertrophy and RVOT enlargement (Figure 5) [52]. Out
of these, localized aneurysms, severe global/segmental
dilatation of the RV and global systolic dysfunction are
considered major criteria while mild global/segmental
dilatation of the RV, regional contraction abnormalities
and global diastolic dysfunction are considered minor cri-
teria according to the Task Force [5].
Morphologic and functional abnormalities are found
most commonly in the "triangle of dysplasia" [44]. Tandri
et al systemically described qualitative and quantitative
CMR findings in patients meeting Task Force criteria for
A. Axial black-blood image from a patient with ARVD showing fat infiltration and thinning of the underlying myocardial wall  (arrow) Figure 1
A. Axial black-blood image from a patient with ARVD showing fat infiltration and thinning of the underlying 
myocardial wall (arrow).B. Axial fat-suppressed image from the same patient at the same level showing an irregular epicar-
dial surface of the RV due to fat replacement of the RV (arrow).Journal of Cardiovascular Magnetic Resonance 2008, 10:32 http://www.jcmr-online.com/content/10/1/32
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the diagnosis of ARVD using state-of-the-art CMR [53].
Intra-myocardial fat was noted in a high percentage
(75%) of patients who met the Task Force criteria for
ARVD, more commonly in the basal regions (RV inflow
and outflow) and lateral apex. Trabecular disarray was
seen more frequently than wall thinning and aneurysms.
RV dimensions and volumes usually are significantly dif-
ferent in ARVD compared to normals and hence useful in
the diagnosis of ARVD [54,55].
ECG-gated steady-state free precession imaging (SSFP)
pulse sequences (FIESTA, true-FISP, balanced fast field
echo) have led to improvements in cine CMR in terms of
better contrast between blood and myocardium, better
delineation of endocardial borders and more accurate and
reliable volumetric measurements of the ventricle as com-
pared to segmented k-space cine gradient echo (GRE)
images [e.g. fast low-angle shot (FLASH), fast cardiac-
gated gradient-echo (FASTCARD)] [56]. Signal intensity
in SSFP is not affected by reduction in velocity of flowing
blood in cases of dysfunctional RV as compared to GRE
imaging. Schick et al [57] implemented chemical shift-
selective sequence to breath-hold cine gradient-echo CMR
and found that it improved tissue characterization and
differentiation of areas with fibrosis and fatty degenera-
tion from normal myocardial tissue. The use of chemical
shift fat suppression (Figure 1B) may also better reveal the
true thickness of the RV wall, making the identification of
wall thinning or wall hypertrophy in ARVD more reliable
[52].
Cardiac-gated spin-echo (SE) pulse sequences have con-
ventionally been used for evaluation of cardiac morphol-
ogy. CMR black-blood techniques have been developed
for cardiovascular imaging to improve segmentation of
myocardium from the blood pool. Black blood in the car-
diac chambers is achieved by saturation of inflowing
blood signal both above and below the acquired volume.
Current black blood CMR techniques (Figure 1A) use a
breath-hold fast SE CMR sequence with a dual magnetiza-
tion preparation pulse (double inversion-recovery) [58-
61]. Breath-hold sequences provide end-diastolic images
with reduced motion artifacts and improved resolution of
myocardial detail. Our group found that CMR obtained
using a double R-R fast SE sequence with a short echo time
(TE) of 30 msec, an echo train length (ETL) of 24–32 or
less if possible, a section thickness of 5 mm, and field of
view (FOV) of 24–28 cm were superior to those obtained
using other sequences [61].
Black-blood single shot fast SE sequences employ 180
degrees radiofrequency re-focalization pulses preceded by
an inversion double pulse associated to pre-saturation
pulses. Although these methods substantially reduce
motion artifacts and imaging time, the single shot
approach frequently results in loss of visualization of the
RV. Thus single shot SE is not recommended unless severe
arrhythmia is present resulting in failure of other black
blood sequences. A full CMR protocol for ARVD is shown
in Table 3.
Axial end-diastolic bright-blood image from a patient with  ARVD showing RV dilatation Figure 3
Axial end-diastolic bright-blood image from a patient with 
ARVD showing RV dilatation. Note the diameter of RV is 
greater than LV at the mid-ventricular level.
Axial bright-blood image from a patient with ARVD showing  a subtle 5 mm aneurysm near the moderator band (arrow) Figure 2
Axial bright-blood image from a patient with ARVD showing 
a subtle 5 mm aneurysm near the moderator band (arrow).Journal of Cardiovascular Magnetic Resonance 2008, 10:32 http://www.jcmr-online.com/content/10/1/32
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Role of CMR in diagnosis of ARVD
Sensitivity and specificity of CMR detection of RV intra-
myocardial fat in diagnosis of ARVD is variable, ranging
from 22% to 100% [44,48,52,54,62]. Identifying fat can
be challenging because the RV is a thin structure and areas
of affected myocardium can be quite small. It may be par-
ticularly difficult to distinguish pathologic adipose infil-
tration in areas where adjacent epicardial fat is normally
present such as in AV groove and antero-apical portion of
RV.
Castillo et al [61] demonstrated that even state-of-the-art
clinical CMR protocols using double inversion-recovery
fast SE sequences may be limited in both spatial and con-
trast resolution for detecting fine intra-myocardial struc-
tural detail in ARVD. The presence of signal intensity
increase seen in T1 weighted images is not specific for fat.
Proximity to the surface coil, truncation band artifacts,
and various motion-related artifacts may cause projection
of high signal intensities onto the myocardium and be
mistaken for fat. Similarly, artifacts related to arrhythmia,
breathing motion, and blood flow can also produce high
signal intensity in the free wall of the RV [63].
The varying sensitivities that have been reported for CMR
to detect intra-myocardial fat can be ascribed to patient
selection, which includes not only those with overt forms
of the disease with extensive morpho-functional altera-
tions and inducible arrhythmias, but also those with con-
cealed forms without global dysfunction and without
inducible arrhythmias [62]. Isolated areas of fat replace-
ment have also been reported in elderly patients, long-
term steroid use, other cardiomyopathies and in idio-
pathic RVOT tachycardia, which forms an important dif-
ferential diagnosis of ARVD [52]. Obesity may be
associated with fatty replacement of the RV wall [64].
Macedo et al [65] reported that lipomatous infiltration of
RV on cine CMR may occur without global or regional
functional abnormalities suggestive of ARVD. Thus RV fat
replacement may be a distinct disorder in itself and does
not always imply ARVD.
The reliability of detecting increased intra-myocardial T1
signal is probably low. Bluemke et al [55] reported that
identification of high T1 fat signal is less reliable than RV
measurements or other morphological changes in ARVD.
Abbara at al [63] reported that applying fat-suppressed
sequences to conventional fast spin-echo (FSE) imaging
leads to an increase in the inter-reader reproducibility and
confidence for intra-myocardial fat infiltration, also
allowing identification of even subtle to mild degrees of
intra-myocardial fatty infiltration (although the signifi-
cance of such minor fatty changes with respect to their
association with ARVD is not clear). Tandri at al [54] sim-
ilarly found good inter-observer agreement for fat and
excellent reliability for other qualitative and quantitative
variables among experienced CMR readers by the use of a
uniform imaging protocol and application of fat-suppres-
sion on breath-hold double-inversion recovery blood
suppression pulses. However both Bluemke et al [55] and
Tandri et al [54] concluded that the identification of fat
within the myocardium is the least specific and least
Axial bright-blood image from a patient with ARVD showing  enlargement of RV outflow tract (large arrow) Figure 5
Axial bright-blood image from a patient with ARVD showing 
enlargement of RV outflow tract (large arrow). Note diame-
ter of RV outflow tract is greater than that of the adjacent 
aorta (small arrow).
Short-axial bright-blood image from a patient with ARVD  showing increased trabeculation in the RV (arrows) Figure 4
Short-axial bright-blood image from a patient with ARVD 
showing increased trabeculation in the RV (arrows).Journal of Cardiovascular Magnetic Resonance 2008, 10:32 http://www.jcmr-online.com/content/10/1/32
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Table 3: CMR Protocol for ARVD
1: Sagittal Scout: any rapid image localizer
2: Axial Black Blood Images: double inversion recovery TSE/FSE
Axial imaging plane provides the best view of the right ventricular anterior wall and the right ventricular outflow tract. Prescribe the axial images 
starting from the diaphragm to the pulmonary artery.
TR = 2 R-R intervals
TE = 5 msec (minimum-full) (GE); TE 30 msec (Siemens)
Slice thickness = 5 mm
Interslice gap = 5 mm and
Field of view (FOV) = 28 cm
ETL 16–24
3: Axial SSFP Bright Blood Cine Images
Same superior to inferior coverage as sequence 2.
TR = 3.5 msec (GE); TR 40–50 msec (Siemens)
TE = minimum
Flip angle = 45–70°
Slice thickness = 8 mm
Interslice gap = 2 mm
FOV = 36–40 cm
16–20 views per segment
Parallel imaging n = 2 is optional
4: Vertical and long axis cine images (2, 4 chamber view)
The parameters for this sequence are the same as sequence 3.
5: Short-axis Black Blood Images
The parameters for this sequence are the same as sequence 2.
6: Axial Black Blood Images with Fat Suppression (Optional sequence)
This sequence is optional and usually adds 10 extra minutes to the total scanning time. Repeat series 2 with chemical selective fat suppression.
7: Short-axis SSFP cine
This sequence is prescribed from the four-chamber view. Cover the entire left ventricle. These are performed after gadolinium administration, 
in order to give time for gadolinium washout. The parameters are identical to sequence 3.
8: TI scout
4 chamber view, using TI scout sequences or trial TI times to suppress normal myocardium.
9: Delayed gadolinium short axis images (10–15 min delay)
Same slice coverage as short axis cine images.
TR/TE per manufacturer recommendations
TI : optimized to suppress the left ventricle
Flip angle = 20–25°
Slice thickness = 8 mm
Interslice gap = 2 mm
FOV = 36–40 cm
No parallel imaging
Use phase sensitive inversion recovery if available (PSIR)
10: Delayed gadolinium axial axis images
Same slice coverage as axial cine images. Pulse sequence same as sequence 9.
TI : optimized to suppress the right ventricle
Use phase sensitive inversion recovery if available (PSIR)
Patient preparation: If the patient is known to have frequent ventricular ectopy, the authors recommend the use of oral Metoprolol 50 mg, 1 hour 
prior to the procedure provided that the patient has no contraindications. If ventricular arrhythmias are frequent and will substantially impact image 
quality, the exam should be terminated at this point.
***GADOLINIUM IS ADMINISTERED ACCORDING TO INSTITUTIONAL PROTOCOL (usually 0.15 – 0.2 MMOL/KG)Journal of Cardiovascular Magnetic Resonance 2008, 10:32 http://www.jcmr-online.com/content/10/1/32
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reproducible of any of the other parameters in the CMR
evaluation of ARVD. Furthermore, it should be noted that
fat signal by imaging tests is not a Task Force criterion for
the diagnosis of ARVD.
By the application of CMR, Harper et al [66] confirmed
that RV free wall thinning is independently predictive of
the presence of ARVD. They quantified RV free wall thin-
ning in ARVD and reported that RV free wall thickness
(RVFWT) of less than 5 mm is suspicious for ARVD,
between 5 and 8 mm is indeterminate and greater than 8
mm is highly improbable to represent ARVD. Thinning of
the RV free wall has been noted as a significant abnormal-
ity in ARVD. However, like fat, qualitative evaluation of
CMR RVFWT in ARVD may be compromised by thinness
of the normal RV free wall, limited in-plane resolution,
adjacent high epicardial fat signal and motion artifacts.
Like fat, free-wall thinning is also not a part of the Task
Force criteria.
Late-enhancement (LE) CMR has the potential to identify
myocardial fibro-fatty changes in both RV and LV in
ARVD [51,67]. CMR findings suggesting fibrous tissue
additionally show correlation with histo-pathological
findings and also show association with RV dysfunction
and inducibility of VT on electrophysiological (EP) testing
[51]. Fibro-fatty variety of ARVD is more common than
fatty ARVD. Documentation of fibrous tissue has been
suggested to be diagnostically more important than find-
ing fat alone. Fat replacement of RV without fibrosis prob-
ably represents a distinct clinico-pathological entity that
may not be considered synonymous with ARVD. Fibrous
tissue replacement of the myocardium is also believed to
be more arrhythmogenic than fat alone [68].
A potential role of CMR lies in its ability to detect early
and subtle cases of ARVD which are otherwise insensitive
to diagnosis by Task Force criteria, posing a real diagnostic
dilemma. In patients with structurally severe disease, all
imaging modalities are likely to provide abnormal find-
ings and the ability of CMR to do so therefore does not
stand out [69]. CMR can uniquely detect regional and
diastolic (right and left) ventricular dysfunction [48,70]
which may represent earliest manifestations of ARVD, a
continually evolving and progressive disease.
Regional functional abnormalities of RV in ARVD include
focal hypokinesis (systolic wall thickening of <40%), aki-
nesis (systolic wall thickening of <10%), dyskinesis
(movement of myocardial segment outward in systole),
and aneurysms (segments with persistent bulging in dias-
tole and dyskinetic in systole) [52]. Myocardial tissue tag-
ging may potentially improve the sensitivity of CMR to
detect regional dysfunction in ARVD because visual anal-
ysis is often inadequate due to the complex contraction
pattern of the RV [71]. However, tissue tagging is not eas-
ily applied due to the very thin RV free wall and poor sig-
nal to noise ratio [52].
Regional functional abnormalities have been shown to
correlate with areas of signal abnormality. The presence of
regional abnormal wall motion associated with signal
abnormality is more suggestive of ARVD than either of
them alone [52]. Abnormal diastolic dysfunction has
been shown to correlate with morphologic abnormalities,
indicating that global diastolic dysfunction accompanies
more extensive morphologic alterations in patients with
ARVD [48,72]. In our experience, regional delayed and
dyssynchronous contraction of the RV (mostly at the
A. Axial end-diastolic bright-blood image from a patient with ARVD. The basal free wall (arrow) appears smooth and regular,  with no aneurysms Figure 6
A. Axial end-diastolic bright-blood image from a patient with ARVD. The basal free wall (arrow) appears 
smooth and regular, with no aneurysms. B. Axial end-systolic bright-blood image from the same patient. A small aneu-
rysm forms at the basal free wall due to dyssynchronous contraction of the RV (arrow).Journal of Cardiovascular Magnetic Resonance 2008, 10:32 http://www.jcmr-online.com/content/10/1/32
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base) is present in about one-third of phenotypically con-
firmed cases of ARVD with no other CMR findings of
ARVD. We have also found that dyssynchronous contrac-
tion of the RV basal free wall may represent an early phe-
notypic expression of desmosomal mutations (especially
PKP2) in the RV in asymptomatic first-degree relatives of
ARVD pro-bands. This finding showed good correlation
with electrocardiographic minor criteria and inducibility
for ventricular arrhythmias (Figure 6).
MR imaging is a useful tool in the evaluation of patients
with suspected ARVD. However, it is important to recog-
nize that CMR is not a "gold standard" for the diagnosis
of ARVD. But rather, CMR is one of a number of tests
which should be employed in the evaluation of patients
with suspected ARVD. Other tests which should be per-
formed include a 12 lead electrocardiogram (ECG), sig-
nal-averaged ECG (SAECG), Holter monitor, stress test,
and echocardiogram. If these tests suggest ARVD, we at
our institution, typically recommend biopsy to confirm
the diagnosis and exclude other potential etiologies (such
as sarcoidosis) mainly in sporadic cases as well as EP study
as a part of risk stratification [73]. Great caution must be
employed when the only abnormalities which are seen are
observed with CMR. In our experience, CMR imaging can
result in an over-diagnosis of ARVD. As noted above,
many abnormalities which can be seen with CMR, partic-
ularly wall thinning and the presence of fat are nonspe-
cific findings. This is important as misdiagnosis of ARVD
has great implications not only for the patient but for the
family as well. It is extremely uncommon to have an
entirely normal 12 lead ECG and have ARVD. Therefore,
CMR abnormalities observed in a patient with a normal
12 lead ECG should be interpreted with great caution
[74].
Currently, two large clinical trials are under-way that use
CMR for ARVD diagnosis. The European ARVD registry
[75] attempts prospective validation of criteria for clinical
diagnosis of ARVD, evaluation of accuracy of clinical diag-
nosis and assessment of the natural course of disease [52].
The Multidisciplinary Study of Right Ventricular Dysplasia
(U.S. ARVD study) [76] aims to prospectively enroll 100
ARVD patients with 500 first-degree relatives with the fol-
lowing scientific goals: 1) to study a large group of newly
diagnosed patients with this uncommon disorder, 2) to
elucidate the genetic etiology of this disease, 3) to evaluate
treatment of ARVD in these patients. These studies may
help better define the role of CMR in ARVD in cases and
family members.
Left ventricular involvement in ARVD
Introduction
LV involvement in ARVD has been increasingly described,
with prevalence reported as 16% [42] to 76% [77]. Hebert
et al [78] reported a subnormal LV ejection fraction (EF)
by angiography in 20% of a group of ARVD patients.
Hunold et al [67] detected LE in the LV in 2 of 6 ARVD
patients. Peters and Reil [79] reported that despite a nor-
mal LVEF, 40% of their 60 ARVD patients had LV wall
motion abnormalities. Bauce et al [31] found LV abnor-
malities in half of the patients in their study population
with echocardiographic evidence of ARVD. Sen-Chowd-
hry et al [36] demonstrated LV abnormalities with pre-
served RV function in 40% of their ARVD cohort.
Lindstrom et al [80] demonstrated LV abnormalities in
93% of their ARVD patients by myocardial perfusion scin-
tigraphy and echocardiography. Manyari et al [81] discov-
ered latent LV dysfunction to be present in all cases of
ARVD by uncovering it during exercise testing. Evolution
of LV involvement in ARVD has been demonstrated in
terms of appearance of new abnormalities or worsening of
existing abnormalities or both, with progression of RV
disease on long-term follow-up.
These cases of early and/or predominant LV involvement
in ARVD have brought into question the traditional con-
sideration of LV involvement as only an end-stage compli-
cation of progressive RV dilatation and dysfunction in
ARVD. Although there is not a complete agreement in lit-
erature, LV involvement in ARVD may not stand for a sep-
arate disorder, but may be part of a larger disease process
extending across the entire heart supporting the adoption
of a broader term "arrhythmogenic cardiomyopathy" with
appropriate sub-classifications [36].
Axial bright-blood image from a patient with ARVD showing  a thinned lateral wall of the LV (arrow) due to fatty replace- ment Figure 7
Axial bright-blood image from a patient with ARVD showing 
a thinned lateral wall of the LV (arrow) due to fatty replace-
ment.Journal of Cardiovascular Magnetic Resonance 2008, 10:32 http://www.jcmr-online.com/content/10/1/32
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Mechanisms of LV involvement in ARVD
The most common variant of ARVD has been postulated
to be biventricular with LV involvement from its early
stages. The rationale for this is the classification of ARVD
as a desmosomal disease and desmosomal genes are
expressed in both ventricles. Desmosomal mutations that
primarily affect cell adhesion may affect the distensible,
thin-walled RV earlier in the course of the disease. LV dys-
function in ARVD may also be secondary to the enlarged
and poorly functioning RV because physiologically heart
cannot be compartmentalized into functionally inde-
pendent right and left sides.
Clinical expression of LV involvement
LV involvement in classic ARVD is characterized by exten-
sion of T-wave inversion in the ECG lateral leads (V5, V6,
L1, aVL), arrhythmia of LV or biventricular origin, and/or
isolated LV dilatation and impairment [36]. ARVD fatty/
fibro-fatty changes of LV myocardium can extend across
varying thickness of myocardial circumference, with a pre-
dilection for the sub-epicardial and mid-ventricular wall
(Figure 7). Fibro-fatty changes can affect both the septum
and more often, the LV free wall, either diffusely or region-
ally with a predilection for postero-septal and postero-lat-
eral areas [77]. Myocardial replacement of LV by adipose
or fibro-adipose tissue, like the RV, is believed to progress
inwards from the subepicardium to the trabecular myo-
cardium [82].
Fibro-fatty replacement of the LV shows correlation with
myocardial perfusion defects predominantly located in
antero-septal and basal posterior segments of the LV, adja-
cent to the parts of the RV most frequently affected by the
disease [80]. Other quantitative and qualitative LV abnor-
malities that have reportedly been noted in ARVD, like
RV, include increased LV end-diastolic pressure, decreased
EF, AV block, regional wall motion abnormalities, aneu-
rysms (most frequently at the apex), presence of asynergic
areas (most frequently located at the apex or the infero-
posterior wall) and dilatation [83].
LV involvement in ARVD appears histologically similar to
the RV findings or is only fibrotic [83]. Pinamonti et al
found discrete small diverticula of the LV wall on angiog-
raphy which were thought to represent some localized
muscle defect as a component of the underlying ongoing
dysplastic process [83]. LV involvement has been detected
even in asymptomatic patients and in those with a short
duration of symptoms [80,84,85]. LV involvement is
more common and more severe in families with several
members affected with ARVD [83,86]. LV involvement is
associated with increased myocardial mass, inflammatory
infiltrates, clinical arrhythmic events and more severe RV
wall thinning and heart failure. Frank left-sided heart fail-
ure is unusual.
LV involvement and Task Force criteria
When Task Force criteria were first proposed, minimal LV
disease was a stipulation, intended to improve specificity
of a then little known disease and ensure distinction from
related disorders such as dilated cardiomyopathy. It
appears likely that descriptions of LV involvement may be
included in subsequent revisions of the diagnostic criteria
for ARVD [41].
Conclusion
ARVD presents a diagnostic challenge on account of the
inherent difficulty in its diagnosis using conventional
methods, lack of clinical experience due to the rare nature
of disease and high frequency of misdiagnosis of the con-
dition. Also, there is no gold standard for its diagnosis and
the Task Force criteria which are currently relied upon
have never been validated. CMR plays an important role
in the diagnosis of ARVD that is both qualitative and
quantitative. The recent expansion of the genetic under-
standing for ARVD will underscore the importance of
noninvasive imaging techniques for early phenotypic
characterization of this disorder.
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